中国癌症杂志
中國癌癥雜誌
중국암증잡지
CHINA ONCOLOGY
2015年
3期
173-178
,共6页
李媛媛%王红艳%吴晓燕%宋瑞卉%李敬
李媛媛%王紅豔%吳曉燕%宋瑞卉%李敬
리원원%왕홍염%오효연%송서훼%리경
胃肿瘤%颗粒蛋白前体%siRNA%细胞衰老
胃腫瘤%顆粒蛋白前體%siRNA%細胞衰老
위종류%과립단백전체%siRNA%세포쇠로
Gastric neoplasms%Progranulin%siRNA%Cell senescence
背景与目的：颗粒蛋白前体(progranulin，PGRN)是一种新型生长因子，在细胞迁移、细胞周期进展及肿瘤形成过程中发挥着重要作用。PGRN在多种恶性肿瘤细胞中高表达，不仅参与肿瘤的生长过程，还与肿瘤的发生、演变过程关系密切。本研究旨在探讨PGRN在胃癌组织中的表达，及其对胃癌BGC823细胞增殖与衰老的影响。方法：利用免疫组化方法检测胃癌组织及癌旁组织中PGRN的表达；利用实时定量聚合酶链反应(quantitative real-time polymerase chain reaction，qRT-PCR)干扰胃癌细胞株BGC823中PGRN的表达；通过四甲基偶氮唑盐(MTT)法、细胞克隆形成和细胞衰老检测实验，探讨PGRN对BGC823细胞增殖与衰老的影响。结果：PGRN在胃癌组织中高表达。PGRN表达降低后，胃癌细胞的增殖与克隆形成能力均显著降低。PGRN-siRNA细胞的克隆形成率为(25.3±3.1)%，对照组细胞的克隆形成率为(72.1±5.7)%，正常组细胞的克隆形成率为(80.3±4.0)%。两两比较，对照组与正常组间差异无统计学意义(P>0.05)，实验组与其他两组间差异均有统计学意义(P均<0.05)。干扰PGRN表达能够明显促进BGC823细胞衰老。PGRN-siRNA细胞衰老阳性率为(27.6±2.1)%，对照组细胞衰老阳性率为(3.2±1.3)%，正常组细胞衰老阳性率为(1.9±1.2)%。两两比较，对照组与正常组间差异无统计学意义(P>0.05)，实验组与其他两组间差异均有统计学意义(P均<0.05)。结论：PGRN可作为新的胃癌标志物，为临床胃癌的靶向治疗提供新的思路。
揹景與目的：顆粒蛋白前體(progranulin，PGRN)是一種新型生長因子，在細胞遷移、細胞週期進展及腫瘤形成過程中髮揮著重要作用。PGRN在多種噁性腫瘤細胞中高錶達，不僅參與腫瘤的生長過程，還與腫瘤的髮生、縯變過程關繫密切。本研究旨在探討PGRN在胃癌組織中的錶達，及其對胃癌BGC823細胞增殖與衰老的影響。方法：利用免疫組化方法檢測胃癌組織及癌徬組織中PGRN的錶達；利用實時定量聚閤酶鏈反應(quantitative real-time polymerase chain reaction，qRT-PCR)榦擾胃癌細胞株BGC823中PGRN的錶達；通過四甲基偶氮唑鹽(MTT)法、細胞剋隆形成和細胞衰老檢測實驗，探討PGRN對BGC823細胞增殖與衰老的影響。結果：PGRN在胃癌組織中高錶達。PGRN錶達降低後，胃癌細胞的增殖與剋隆形成能力均顯著降低。PGRN-siRNA細胞的剋隆形成率為(25.3±3.1)%，對照組細胞的剋隆形成率為(72.1±5.7)%，正常組細胞的剋隆形成率為(80.3±4.0)%。兩兩比較，對照組與正常組間差異無統計學意義(P>0.05)，實驗組與其他兩組間差異均有統計學意義(P均<0.05)。榦擾PGRN錶達能夠明顯促進BGC823細胞衰老。PGRN-siRNA細胞衰老暘性率為(27.6±2.1)%，對照組細胞衰老暘性率為(3.2±1.3)%，正常組細胞衰老暘性率為(1.9±1.2)%。兩兩比較，對照組與正常組間差異無統計學意義(P>0.05)，實驗組與其他兩組間差異均有統計學意義(P均<0.05)。結論：PGRN可作為新的胃癌標誌物，為臨床胃癌的靶嚮治療提供新的思路。
배경여목적：과립단백전체(progranulin，PGRN)시일충신형생장인자，재세포천이、세포주기진전급종류형성과정중발휘착중요작용。PGRN재다충악성종류세포중고표체，불부삼여종류적생장과정，환여종류적발생、연변과정관계밀절。본연구지재탐토PGRN재위암조직중적표체，급기대위암BGC823세포증식여쇠로적영향。방법：이용면역조화방법검측위암조직급암방조직중PGRN적표체；이용실시정량취합매련반응(quantitative real-time polymerase chain reaction，qRT-PCR)간우위암세포주BGC823중PGRN적표체；통과사갑기우담서염(MTT)법、세포극륭형성화세포쇠로검측실험，탐토PGRN대BGC823세포증식여쇠로적영향。결과：PGRN재위암조직중고표체。PGRN표체강저후，위암세포적증식여극륭형성능력균현저강저。PGRN-siRNA세포적극륭형성솔위(25.3±3.1)%，대조조세포적극륭형성솔위(72.1±5.7)%，정상조세포적극륭형성솔위(80.3±4.0)%。량량비교，대조조여정상조간차이무통계학의의(P>0.05)，실험조여기타량조간차이균유통계학의의(P균<0.05)。간우PGRN표체능구명현촉진BGC823세포쇠로。PGRN-siRNA세포쇠로양성솔위(27.6±2.1)%，대조조세포쇠로양성솔위(3.2±1.3)%，정상조세포쇠로양성솔위(1.9±1.2)%。량량비교，대조조여정상조간차이무통계학의의(P>0.05)，실험조여기타량조간차이균유통계학의의(P균<0.05)。결론：PGRN가작위신적위암표지물，위림상위암적파향치료제공신적사로。
Background and purpose:Progranulin (PGRN) is a novel growth factor that plays an important role in the tumorigenicity, tumor cell migration and cell cycle. Its expression in many malignant tumor cells is high. It is not only involved in tumor cell growth, but also closely related with the occurrence and evolution of tumor. This study was to investigate the expression of PGRN in gastric cancer and the effects on proliferation and senescence in gastric cancer cell line BGC823. Methods:Immunohistochemical method was used to detect the expression of PGRN in gastric cancer tissues and adjacent normal tissues; Quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect the expression of PGRN in PGRN-siRNA BGC823 cells;MTT method, cell colony formation and cell senescence experiments were used to explore the effects of PGRN on proliferation and senescence in BGC823 cell. Results:PGRN protein levels were high in gastric cancer tissues;Knocking down the PGRN gene in BGC823 decreased the proliferation and clonogenic capacity, cloning efifciency in PGRN-siRNA group was (25.3±3.1)%, in the control group was (72.1±5.7)%, and in the normal cells was (80.3±4.0)%, there was no signiifcant difference between normal group and control group, but there were signiifcant differences among PGRN-siRNA group and the other two groups (P<0.05);Knocking down the PGRN gene in BGC823 cells could promote cell senescence. The positive rate of aging in PGRN-siRNA group was (27.6±2.1)%, in the control group was (3.2±1.3)%, and in the normal group was (1.9±1.2)%, there was no signiifcant difference between normal group and control group. But there were signiifcant differences among PGRN-siRNA group and the other two groups (P<0.05). Conclusion:PGRN can be used as a new marker for gastric cancer, and provide new ideas to the treatment of gastric cancer.
